BridgeBio Pharma Inc

NASDAQ:BBIO   3:59:50 PM EDT
11.60
+0.72 (+6.62%)
Products

Bridgebio Pharma Announces Positive Phase 1 Data And Phase 2/3 Trial Design For Bbp-711, A Potentially Best-In-Class Go Inhibitor For Primary Hyperoxaluria Type 1 (Ph1) And Recurrent Kidney Ston

Published: 06/27/2022 11:41 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for Bbp-711, a Potentially Best-in-class Go Inhibitor for Primary Hyperoxaluria Type 1 (ph1) and Recurrent Kidney Stone Formers.
Bridgebio Pharma Inc - Bridgebio Has Met With Regulators and Intends to Initiate a Phase 2/3 Pivotal Study by End of 2022.
Bridgebio Pharma Inc - at End of 2022, Bridgebio Also Intends to Launch a Phase 2 Study of Bbp-711 in Adult Recurrent Kidney Stone Formers.
Bridgebio - Bbp-711 Led to Near Complete Inhibition of Glycolate Oxidase Throughout Dosing Period, Greater Than 10-fold Increases in Plasma Glycolate.